Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alfa + Zeprumetostat + Apatinib + CAPOX in First-Line Metastatic Gastric/GEJ Adenocarcinoma
NCT07874425Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2026
- Primary completion
- Dec 2028
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa and zeprumetostat in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Fudan University. Primary endpoint: Objective Response Rate up to 2 years. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfazeprumetostat
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07874425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07874425.